The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?

被引：7
|
作者：
Grant, S
机构：
[1] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Dept Pharmacol, Richmond, VA 23298 USA
来源：
LEUKEMIA | 2004年 / 18卷 / 12期
关键词：
D O I：
10.1038/sj.leu.2403522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1931 / 1933
页数：3
相关论文
共 50 条
  • [41] Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
    Newbold, Andrea
    Lindemann, Ralph K.
    Cluse, Leonie A.
    Whitecross, Kate F.
    Dear, Anthony E.
    Johnstone, Ricky W.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (05) : 1066 - 1079
  • [42] Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3
    Bali, P
    George, P
    Cohen, P
    Tao, JG
    Guo, F
    Sigua, C
    Vishvanath, A
    Scuto, A
    Annavarapu, S
    Fiskus, W
    Moscinski, L
    Atadja, P
    Bhalla, K
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 4991 - 4997
  • [43] Synthesis of a novel histone deacetylase inhibitor
    Liu, T
    Kapustin, G
    Etzkorn, FA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U594 - U595
  • [44] MAINTENANCE OF NORMAL HEMATOPOIETIC PROGENITOR CELLS BY THE DEACETYLASE INHIBITOR LAQ824 IS ASSOCIATED WITH INDUCTION OF NOTCH TARGET GENES
    Bug, G.
    Romanski, A.
    Ottmann, O. G.
    Scott, J. W.
    Serve, H.
    Schwarz, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 6 - 6
  • [45] Re: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
    Samid, D
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (05) : 475 - 476
  • [46] Combined treatment with histone deacetylase inhibitor LAQ824 and Apo-2L/TRAIL: Mechanistic basis of superior activity against human acute leukemia and CML-BC cells.
    Li, YQ
    Guo, F
    Sigua, C
    Tao, JG
    Bali, P
    Vishvanath, A
    Gutti, R
    George, P
    Moscinski, L
    Atadja, P
    Bhalla, KN
    BLOOD, 2003, 102 (11) : 595A - 595A
  • [47] Effects of the hydroxamic acid histone deacetylase inhibitors trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and LAQ824 on histone and protein acetylation.
    Kristeleit, RS
    Stimson, L
    Workman, P
    Aherne, GW
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6107S - 6107S
  • [48] Application of Histone Deacetylase Inhibitor in Acute Myeloid Leukemia
    Chen, Dan-Dan
    Qin, Ke-Ning
    Lu, Chun-Li
    Zeng, Jian-Ye
    Wang, Xiao-Min
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2024, 51 (06) : 1393 - 1405
  • [49] The Histone Deacetylase Inhibitor LAQ824 Maintains Normal Hematopoietic Progenitor cells (HPC) Associated with Induction of Notch Target Genes and Does Not Eliminate Leukemic HPC in Vitro
    Schwarz, Kerstin
    Ottmann, Oliver
    Romanski, Annette
    Vogel, Anja
    Scott, Jeffrey W.
    Serve, Hubert
    Bug, Gesine
    BLOOD, 2008, 112 (11) : 486 - 487
  • [50] Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
    Kong, Yi-Lin
    Pan, Bi-Hui
    Liang, Jin-Hua
    Zhu, Hua-Yuan
    Wang, Li
    Xia, Yi
    Wu, Jia-Zhu
    Fan, Lei
    Li, Jian-Yong
    Xu, Wei
    AGING-US, 2020, 12 (16): : 16083 - 16098
12345